Urological Oncology: Testis Cancer and

1 Advances in Oncologic Therapy 50

2 51
3 52
4 53
5 Re: Non-Guideline-Concordant Treatment of Testicular Cancer is Associated 54
6 with Reduced Relapse-Free Survival 55
7 56
8 P. Paffenholz, I. M. Heidegger, K. Kuhr, S. H. Loosen, D. Pfister and A. Heidenreich 57
9 58
Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, and Institute of Medical Statistics, Informatics and
10 Epidemiology, University Hospital Cologne, Cologne and Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany, and 59
11 Department of Urology, Medical University Innsbruck, Innsbruck, Austria 60
12 Clin Genitourin Cancer 2018; 16: e243ee250. doi: 10.1016/j.clgc.2017.08.018 61
13 62
14 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/28964691 63
15 64
16 Editorial Comment: A complex multimodal approach is required for successful management of 65
17 testicular cancer. Although guidelines are widely available from a variety of sources, nonguideline 66
18 concordant treatment of testicular cancer is still commonplace. The authors retrospectively analyzed 67
19 patients with testicular cancer referred to their department during a 1-year period and compared 68
20 treatment to European Association of Urology guideline recommendations. Of 131 primary treated pa- 69
21 70
tients 23 (18%) received a nonguideline concordant treatment, with the most common error being
22 71
undertreatment due to missing chemotherapy cycles. Undertreatment of patients resulted in signifi-
23 72
24 cantly reduced relapse-free survival compared to guideline concordant treatment (p ¼ 0.005). 73
25 74
26 Jerome P. Richie, MD 75
27 76
28 Re: Paediatric Testicular Tumours in a New Zealand Centre 77
29 78
30 T. Little, S. Lala and V. Upadhyay 79
31 Division of Paediatric Surgery, Department of Paediatrics and Child Health, Wellington Regional Hospital, Wellington, and Divisions of Paediatric Surgery 80
32 and Paediatric Urology, Department of Paediatric Surgery, Starship Children’s Hospital, Auckland, New Zealand 81
33 N Z Med J 2017; 130: 68e72. 82
34 83
35 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/29240742 84
36 85
37 Editorial Comment: Pediatric testicular tumors are relatively rare. The authors have reviewed a 86
38 12-year single center experience as well as the world literature on pediatric testicular tumors. A total 87
39 of 33 tumors in patients younger than age 16 years was described, with 22 being malignant. As ex- 88
40 pected, mature teratoma was the most common tumor. No patient presented with testicular torsion. 89
41 This experience, similar to those of major centers around the world, provides insights into man- 90
42 91
agement, including the practice of selected testis sparing surgery.
43 92
44 93
Jerome P. Richie, MD
45 94
46 95
47 96
48 97
49 98

0022-5347/18/2005-0001/0 https://doi.org/10.1016/j.juro.2018.07.060
THE JOURNAL OF UROLOGY® Vol. 200, 1, November 2018
Ó 2018 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. Printed in U.S.A.

www.jurology.com j 1

Dochead: Urological Survey LIT 5.5.0 DTD
JURO15747_proof
6 August 2018
1:28 pm
EO: